Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.49 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553482 | 1.00 | PPARA (0.49) | PPARAPPARGCYP2D6SRCMMP8 | |
| SCHEMBL17653645 | 1.00 | PPARA (0.49) | PPARAPPARGCYP2D6SRCMMP8 | |
| SCHEMBL27688938 | 0.89 | PTGS2 (0.53) | PPARAPPARGALDH1A1CYP1A2 | |
| SCHEMBL13491149 | 0.86 | ALDH1A1 (0.47) | PPARAPPARGMMP8ALDH1A1CYP3A4 | |
| SCHEMBL6972548 | 0.86 | MMP8 (0.44) | PPARAPPARGMMP8ALDH1A1CYP3A4 | |
| SCHEMBL24327752 | 0.85 | FFAR1 (0.47) | PPARAPPARGALDH1A1POLBLMNA | |
| SCHEMBL10355170 | 0.85 | ESR1 (0.44) | PPARACYP2D6SRCALDH1A1CYP3A4 | |
| SCHEMBL16672673 | 0.85 | MMP8 (0.54) | MMP8ALDH1A1LMNA | |
| SCHEMBL5322346 | 0.85 | ALDH1A1 (0.46) | PPARAPPARGMMP8ALDH1A1CYP3A4 | |
| SCHEMBL17724542 | 0.85 | PPARA (0.47) | PPARAPPARGCYP2D6SRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-6943175-B2 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | NSUN3, TRMT1, NOP2 | PPARA 3763/4885PPARG 3524/4885CYP2D6 1298/4885 |
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | PPARA 1857/4885PPARG 1211/4885CYP2D6 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.